Journal
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS
Volume 14, Issue 2, Pages 146-153Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1534734615580018
Keywords
biomaterials; diabetic foot ulcers; wound healing; neuropeptides; endothelial precursor cells
Categories
Funding
- National Institutes of Health (NIH) [1R24DK091210-01]
- Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BD/48624/2008]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/48624/2008] Funding Source: FCT
Ask authors/readers for more resources
Diabetic foot ulcers (DFU) represent a severe health problem and an unmet clinical challenge. In this study, we tested the efficacy of novel biomaterials in improving wound healing in mouse models of diabetes mellitus (DM). The biomaterials are composed of alginate- and deoxyribonucleic acid (DNA)-based gels that allow incorporation of effector cells, such as outgrowth endothelial cells (OEC), and provide sustained release of bioactive factors, such as neuropeptides and growth factors, which have been previously validated in experimental models of DM wound healing or hind limb ischemia. We tested these biomaterials in mice and demonstrate that they are biocompatible and can be injected into the wound margins without major adverse effects. In addition, we show that the combination of OEC and the neuropeptide Substance P has a better healing outcome than the delivery of OEC alone, while subtherapeutic doses of vascular endothelial growth factor (VEGF) are required for the transplanted cells to exert their beneficial effects in wound healing. In summary, alginate and DNA scaffolds could serve as potential delivery systems for the next-generation DFU therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available